What is F4808N?
F4808N is the short name for RYR1 p.Phe4808Asn. Genetic testing documented this variant in affected members of my family.
RYR1 p.Phe4808AsnPatient-led researchUpdated August 13, 2026
Research question 001
The F4808N RYR1 research project.
We must know what changes before we choose what to fix.
I am Avi Swerdlow. I have an inherited RYR1 variant called F4808N. Other members of my family have the same variant.
I coordinate a patient-led research project. The project aims to measure the effect of F4808N in human muscle.
The project has no treatment result. It has no treatment candidate.
01
Project
What does the F4808N project test?
RYR1 helps skeletal muscle cells release calcium. This calcium release helps a muscle contract.
Different RYR1 variants can change this process in different ways. The project does not yet know the F4808N mechanism.
First, the project must measure the effect of F4808N. This result will help select the next useful test.
What will this project do?
This patient-led project will measure how F4808N affects human muscle.
Does the project have a treatment?
No. The project has no treatment result and no treatment candidate.
What is still unknown?
The project does not know the exact functional effect of F4808N.
01A
Evidence line
How did the evidence reach this point?
Each item has a different role. A publication is not a functional result.
- Phenotype record
A family phenotype entered the literature.
The paper described central core disease before researchers linked it to RYR1.
PMCID PMC492184 ↗ - Variant report
Researchers reported F4808N in RYR1.
The paper placed the variant in the C-terminal region of the RYR1 channel.
PMID 12565913 ↗ - Cohort context
A cohort measured muscle changes in RYR1-related myopathies.
The study used muscle MRI. It gives context, but it does not give an F4808N functional result.
DOI 10.3233/JND-200549 ↗ - Project work
This project started to define a human-muscle test.
The first cell-banking step is complete. The muscle model and functional result do not exist.
Project review, August 13, 2026
These are selected documentary milestones. They do not show progress toward a treatment.
02
Work sequence
What is the four-stage research plan?
Each stage must give sufficient evidence for the next stage.
- 01
Define the model
Define patient-derived muscle cells, matched controls, and quality requirements.
In progress - 02
Measure the effect
Measure calcium handling, muscle force, RNA, and RyR1 protein.
Planned - 03
Repeat the tests
Repeat each important test across independent clones and test runs.
Planned - 04
Select the next method
Select a treatment method only when the data show that the method is applicable.
Not started
A result must pass four gates.
The path changes when a test does not give a repeatable effect.
- Current workQualify the cell model
- Gate 01Measure a repeatable effect
- Gate 02Repeat with independent clones
- Gate 03Confirm in another laboratory
- Gate 04Select the next method
If a repeatable effect does not appearRevise the model or the test.
This is a decision rule. It is not a forecast.
03
Current state
What is the current project status?
The project now defines the cell model, matched controls, quality requirements, tests, agreements, and funding.
Evidence, work, and results have different states.
Each row has a direct status label. These categories are not a percentage of completion.
ItemStatus on August 13, 2026
Family genetic evidenceEstablished
Public RYR1 contextAvailable
First cell-banking stepComplete
Patient-derived muscle modelNot complete
Repeatable F4808N muscle effectNot known
Rescue resultNo result
Treatment candidateNot selected
04
Technical plan
What is the technical plan?
The project tests whether F4808N causes repeatable changes in calcium handling, muscle force, RNA, or RyR1 protein.
Target variant
RYR1 p.Phe4808Asn, also called F4808N.
Primary question
Does F4808N cause a repeatable change in calcium handling, muscle force, RNA, or RyR1 protein?
Cell model
The project will reprogram patient cells as induced pluripotent stem cells, or iPSCs. It will use these cells to make muscle cells.
Test design
The design requires matched control cells, independent clones, and independent test runs.
Decision rule
The project will not select a treatment method until the model shows a repeatable effect. Another laboratory must confirm each important result.
Patient-led does not mean patient-only. Qualified laboratories and institutions must control the scientific work.
Consent and institutional agreements must control each transfer of biological material or data.
What will the muscle model measure?
Each measurement tests a different part of the biological question.
Planned modelPatient-derived skeletal muscle
- 01RNAAllele-specific RNA
- 02ProteinTotal RyR1 protein
- 03CalciumResting calcium
- 04Calcium storeStored calcium
- 05Calcium releaseResponse after stimulation
- 06ForceStimulated muscle force
These are planned measurements. This graphic shows no biological result.
05
Public sources
Which public sources support this page?
These sources give background information. They do not give a treatment result for F4808N.
01U.S. National Library of MedicineRYR1 gene02PMID 12565913Principal mutation hotspot for central core disease and related myopathies in the C-terminal transmembrane region of the RYR1 gene.03DOI 10.3233/JND-200549Ryanodine Receptor 1-Related Myopathies: Quantification of Intramuscular Fatty Infiltration from T1-Weighted MRI.04PMCID PMC492184Central core disease. A correlated genetic, histochemical, ultramicroscopic, and biochemical study.
The 1975 paper predates the discovery of RYR1. It gives only historical family and phenotype information. Current project status comes from a project review dated August 13, 2026.
06
Contact
How can researchers contact Avi Swerdlow?
I want to speak with people who work on RYR1 biology, muscle models, calcium tests, sequencing, and rare-disease research.
Email Aviaviswerdlow@gmail.comA scientific discussion is not an institutional commitment. Formal agreements must control all research work.